COMMUNIQUÉS West-GlobeNewswire

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

04/03/2024 - 22:17

PALO ALTO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that it [...]

Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting

04/03/2024 - 22:15

New data advances understanding of new approaches to treating Alzheimer’s disease Research on disease progression could help inform future clinical trials CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc [...]

Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04/03/2024 - 22:15

DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to [...]

SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024

04/03/2024 - 22:09

SANTA CLARA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company [...]

Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States

04/03/2024 - 22:06

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that regulatory submissions were [...]

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

04/03/2024 - 22:05

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results ROCKVILLE, MD, March 4, 2024 — MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling [...]

Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024

04/03/2024 - 22:05

SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians [...]

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

04/03/2024 - 22:05

ROCKVILLE, Md., March 04, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]

OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis

04/03/2024 - 22:05

WARSAW, Ind., March 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS a company focused exclusively on advancing the field of pediatric orthopedics, today announced it [...]

Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook

04/03/2024 - 22:05

Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 million Guiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- [...]

Stereotaxis Reports 2023 Full Year Financial Results

04/03/2024 - 22:05

ST. LOUIS, March 04, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth [...]

Health Catalyst to Participate in Upcoming Investor Conferences

04/03/2024 - 22:05

SALT LAKE CITY, March 04, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced [...]

Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024

04/03/2024 - 22:01

SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc . (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic [...]

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

04/03/2024 - 22:01

–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of [...]

Cytokinetics to Participate in March Investor Conferences

04/03/2024 - 22:00

SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences in March: [...]

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

04/03/2024 - 22:00

WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]

Avadel Pharmaceuticals Issues Statement On Patent Litigation

04/03/2024 - 21:37

DUBLIN, Ireland, March 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), today issued a statement in response to a jury ruling from the United States District Court for the District of Delaware (“ [...]

Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to April 3, 2024

04/03/2024 - 20:25

MIAMI, March 04, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ”), a special purpose acquisition company, announced today that on March 1, 2024, its sponsor, [...]

Better Choice to Explore Non-Equity Related Capital Solutions to Fund the R&D of its Domestic Animal Targeted GLP1 Supplement

04/03/2024 - 20:00

NEW YORK, March 04, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced that after successfully completing the acquisition [...]